ACUR - ACURA PHARMACEUTICALS, INC

0.01
0.010   95.000%

Share volume: 120
Last Updated: 03-19-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$0.00
0.01
19.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
1,900.00%
3 Months
1,900.00%
6 Months
4,900.00%
1 Year
-50.00%
2 Year
66.67%
Key data
Stock price
$0.01
P/E Ratio 
N/A
DAY RANGE
$0.01 - $0.01
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.02
52 WEEK CHANGE
-$50.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$120
AVERAGE 30 VOLUME 
$160
Company detail
CEO: Robert B. Jones
Region: US
Website: acurapharm.com
Employees: 10
IPO year: 2017
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Acura Pharmaceuticals, Inc. engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. Nexafed products are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.

Recent news